We engineer the best drug candidates by applying high-throughput screening systems and optimization techniques.
Science
Leveraging cutting-edge science and technology to identify and propel best-in-class biologics to the clinic.
Paragon employs a breadth of protein engineering technologies to perform biologics discovery and optimization. We have built a team of exceptional leaders in drug discovery and development who work with top-tier partners to develop transformative programs.
Pipeline
Fueling a pipeline of best-in-class therapies for a range of diseases.
Our business model centers on bringing transformative therapies to patients as rapidly as possible. Our product candidate pipeline demonstrates our progress, with multiple programs in the clinic and the leading program having entered the clinic less than two years from ideation.
Programs
Discovery
Ind-Enabling
Clinical
Rights/Partner
PR004 (APG777)
PR001 (APG808)
PR007 (APG990)
PR012 (APG222)
PR018 (APG333)
Rights/Partner
Apogee Therapeutics is the first company to be formed around assets discovered by and licensed from Paragon. Established in 2022, Apogee is advancing a pipeline of potentially best-in-class product candidates targeting clinically validated biology and well-established development pathways to address the needs of the millions of people living with immunological and inflammatory disorders.
Programs
Discovery
Ind-Enabling
Clinical
Rights/Partner
PR011 (SPY001)
PR010 (SPY002)
PR014 (SPY003)
PR026 (SPY120)
PR022 (SPY130)
PR025 (SPY230)
Rights/Partner
Spyre Therapeutics is the second company to be formed around assets discovered by and licensed from Paragon. Established in 2023, Spyre is advancing a pipeline of product candidates that maximize the efficacy, safety, and convenience of treatments for inflammatory bowel disease (IBD), combining best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to potentially transform the treatment paradigm.
Programs
Discovery
Ind-Enabling
Clinical
Rights/Partner
PR035 (ORKA-001)
PR029 (ORKA-002)
PR059 (ORKA-003)
Rights/Partner
Oruka Therapeutics is the third company to be formed around assets discovered by and licensed from Paragon. Established in 2024, Oruka is advancing a pipeline of potentially best-in-class biologics that aim to redefine the standard of care for patients with chronic skin diseases, including plaque psoriasis.
Programs
Discovery
Ind-Enabling
Clinical
Rights/Partner
PR030 (JADE-001)
PR041 (JADE-002)
PR050 (JADE-003)
Rights/Partner
Jade Biosciences is the fourth company to be formed around assets discovered by and licensed from Paragon. Jade is developing a pipeline of potentially best-in-class therapies to redefine the standard of care for patients living with autoimmune conditions.
Programs
Discovery
Ind-Enabling
Clinical
Rights/Partner
PR054 (CR-001)
PR062 (CR-002)
PR023 (CR-003)
Rights/Partner
Crescent Biopharma is the fifth company to be formed around assets discovered by and licensed from Paragon. Crescent is advancing a pipeline of precision-engineered molecules designed to advance care for patients with solid tumors.
Programs
Discovery
Ind-Enabling
Clinical
Rights/Partner
PR002
PR013
Rights/Partner
Undisclosed
Programs
Discovery
Ind-Enabling
Clinical
Rights/Partner
Multiple internal programs
Rights/Partner
Partners
Driving rapid progress and patient impact.
Our scientific approach and expertise have generated the assets that serve as the foundation for several successful companies devoted to bringing transformative treatments to patients living with significant unmet medical conditions.
ABOUT APOGEE THERAPEUTICS
Apogee Therapeutics is a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the millions of people living with immunological and inflammatory disorders. Apogee is building a pipeline of product candidates targeting clinically validated biology and well-established development pathways. Based in San Francisco, CA, Apogee was founded in 2022 by Fairmount and Venrock Healthcare Capital Partners and is backed by leading healthcare investors. Visit their website for more details. Follow Apogee on LinkedIn.
ABOUT SPYRE THERAPEUTICS
Spyre Therapeutics is a biotechnology company advancing a robust pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD. The company was founded in 2023 by Fairmount and is based in Waltham, MA. Visit their website for more details. Follow Spyre on LinkedIn.
ABOUT ORUKA THERAPEUTICS
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were licensed from Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. Visit their website for more details. Follow Oruka on LinkedIn.
ABOUT JADE BIOSCIENCES
Jade Biosciences is developing transformative therapies with the goal of redefining the standard of care for autoimmune diseases. The company launched in July 2024 and has raised $300 million from a strong slate of investors: Fairmount, Venrock Healthcare Capital Partners, Deep Track Capital, Driehaus Capital Management, Franklin Templeton, RTW Investments, Braidwell LP, Frazier Life Sciences, and Versant Ventures. Jade’s portfolio was licensed from Paragon Therapeutics. Visit their website for more details. Follow Jade on LinkedIn.
ABOUT CRESCENT BIOPHARMA
Crescent BioPharma is a biotechnology company dedicated to advancing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors. The company’s pipeline of three programs harness proven biology to accelerate the path to market for potentially best in class therapeutics. Visit their website for more details. Follow Crescent on LinkedIn.
Team
Dedicated experts with a passion for improving health outcomes.
Paragon is led by a collaborative team of innovators with deep expertise in biologics engineering and development. Together, we are motivated to tackle some of the toughest disease areas and improve quality of life for patients.
Susanna High, MBA
Chief Executive Officer
View Bio
Evan Thompson, Ph.D.
CHIEF OPERATING OFFICER
View Bio
Hussam Shaheen, Ph.D.
HEAD OF RESEARCH
View Bio
Keri Lantz
HEAD OF FINANCE
View Bio
Damon Banks, Ph.D., J.D.
HEAD OF LEGAL
View Bio
Ghassan Fayad, Ph.D.
Vice President, Head of Drug Metabolism and Pharmacokinetics
View Bio
Jason Oh, Ph.D.
SENIOR VICE PRESIDENT OF BIOLOGY
View Bio
Shawn Russell, Ph.D.
SENIOR VICE PRESIDENT OF CHEMISTRY, MANUFACTURING, AND CONTROLS
View Bio
Neta Batscha
SENIOR VICE PRESIDENT OF CORPORATE STRATEGY AND OPERATIONS
View Bio
Michael Meehl, Ph.D.
SENIOR VICE PRESIDENT OF BIOLOGICAL RESEARCH
View Bio
Cyrus Stacey
VICE PRESIDENT OF QUALITY
View Bio
Joe Russo
EXECUTIVE DIRECTOR OF FINANCE PLANNING AND ANALYSIS
View Bio
Archit Sheth-Shah
SENIOR DIRECTOR OF PORTFOLIO STRATEGY
View Bio
Byron Kwan, Ph.D.
DIRECTOR OF BIOTHERAPEUTICS
View Bio
Bernard Liu, Ph.D.
DIRECTOR OF BIOTHERAPEUTICS
View Bio
Danielle Malloy
DIRECTOR OF LEGAL OPERATIONS
View Bio
Daniel Rios, Ph.D.
DIRECTOR OF BIOLOGY
View Bio
Pamela Howley
DIRECTOR OF CHEMISTRY, MANUFACTURING, AND CONTROLS
View Bio
Andrew Schirmer
Associate Director of Manufacturing
View Bio
M. Murshid Alam, Ph.D.
PRINCIPAL SCIENTIST
View Bio
Erin Clark, Ph.D.
PRINCIPAL SCIENTIST
View Bio
Byong Ha Kang, Ph.D.
PRINCIPAL SCIENTIST
View Bio
Jake Milligan, Ph.D.
PRINCIPAL SCIENTIST
View Bio
Kevin Kramer, Ph.D.
Senior Scientist
View Bio
Lauren Maslin, Ph.D.
SENIOR ASSOCIATE
View Bio
Rita Vaz, Ph.D.
SENIOR DIRECTOR OF PROGRAM AND ALLIANCE MANAGEMENT
View Bio
Soraia Oliveira, Ph.D.
Senior Project Manager for Antibody Discovery and Development
View Bio
Joana Ministro, Ph.D.
SENIOR PROJECT MANAGER FOR ANTIBODY DISCOVERY AND DEVELOPMENT
View Bio
Joana Vidal Silva
PROJECT MANAGER FOR ANTIBODY DISCOVERY AND DEVELOPMENT
View Bio
Inês Castro, Ph.D.
Project Manager for Antibody Discovery and Development
View Bio
Mark Heffernan
SENIOR DIRECTOR AND CORPORATE CONTROLLER
View Bio
Melissa Donnarummo
Director of Project Accounting
View Bio
Jodie Raye
SENIOR ACCOUNTANT
View Bio
Eric Pohle
ASSOCIATE DIRECTOR OF FINANCIAL PLANNING AND ANALYSIS
View Bio
Jill Igoe
ACCOUNTS PAYABLE MANAGER
View Bio
Lauren Gillis
DIRECTOR OF EXECUTIVE ADMINSTRATION
View Bio
Sophia Medina
ADMINISTRATIVE ASSISTANT
View Bio
Alison Fiore
ADMINISTRATIVE ASSISTANT
View Bio
About Us
Paragon was founded by Fairmount in 2021 as the firm’s discovery engine for best-in-class biologics and complex biologics. Leveraging a dedicated in-house team of scientific experts in antibody development, Paragon pursues unique therapeutic concepts and enables their rapid proof-of-concept validation. Fairmount is dedicated to investing in promising new therapies developed by biotechnology and life science companies.
News
The latest Paragon news and developments.
- All
- Paragon News
- Partner News
- Sort by
- Newest
- Oldest
- Paragon Therapeutics
- Spyre Therapeutics
- apogee Therapeutics
- Oruka Therapeutics
- Jade Biosciences
- Crescent Biopharma
Join Us
Be a part of our innovative team.
We are excited about the future as we advance our state-of-the-art science. Come join our team and help us shape the next generation of biologic treatments.
VALUES
Powered by our dedication and commitment to improve the lives of patients with high unmet needs.
Our values reflect who we are and guide our actions and decisions, empowering everyone to contribute meaningfully to our shared purpose.
Team First
We respect and value each other’s ideas and contributions. We achieve more by working together.
Uphold a High Bar
We build best-in-class therapies that are impactful for patients. We aim to improve with every iteration, striving for long-term excellence.
Experimentalists at Heart
We are open-minded and data-driven. We constantly adapt and evolve as new information emerges.
Bias Toward Action
We work with a sense of urgency to advance therapeutic programs to the clinic rapidly and efficiently.
Keep It Fun
We celebrate our successes and our opportunities to learn. We are passionate about our work and our play.